Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177352 · ClinicalTrials.gov registry record · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
A Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 13,000
- Enrollment target
- 20
- Study locations
NCT07177352: Recruiting Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
NCT07177352 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 13,000 participants, above the 3,838-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (239% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07177352, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 13,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
Florida
- JEM Research LLC - Atlantis
- K2 Medical Research-Winter Garden - Clermont
- K2 Medical Research - The Villages - Lady Lake
- K2 Medical Research, LLC - Maitland
- Visionary Investigators Network- Neurology Aventura - Miami
- Renstar Medical Research - Ocala
- Charter Research - Winter Park/Orlando - Orlando
- Conquest Research - Lake Nona - Orlando
- Alzheimer's Research and Treatment Center - Stuart
California
- Sun Valley Research Center, Inc. - Imperial
- Inglewood Clinicals - Inglewood
- Irvine Center for Clinical Research - Irvine
- Healthy Brain Clinic - Long Beach
- Oakland Clinical - Oakland
- Riverside Clinical - Riverside
- Syrentis Clinical Research - Santa Ana
- Cenexel California Neuroscience Research, LLC - Sherman Oaks
Arizona
- Banner Alzheimer?s Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,000 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2035-07-31 |
| Phase | Phase 3 |
What NCT07177352 shows while recruiting
NCT07177352 is an interventional study that assigns participants to a tested intervention. Its 13,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,838-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (239% higher).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT07177352 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07177352 about?
NCT07177352 is a clinical study titled "Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies". This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
What is the current status of trial NCT07177352?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 13,000 participants. The study started on 2025-07-02. Estimated completion is 2035-07-31.
What conditions does trial NCT07177352 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07177352?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT07177352?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177352 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07177352's enrollment target sits among peer trials
13,000 3rd of 147 higher than 145 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI